embecta

Embecta Corp. - a company that was formerly part of Becton Dickinson called BD Diabetes Care, is a manufacturer of diabetes injection devices. BD patented its first insulin syringe in 1924, almost immediately after the invention of insulin. As of April 2022, embecta production facilities located in the United States, Ireland and China allow the production of about 8 billion injection devices per year and serve 30 million patients in 100 countries.

History

2022: Completing separation from Becton Dickinson and entering the NASDAQ exchange

Embecta Corp. (embecta) April 5, 2022 informed Zdrav.Expert about the completion of the separation from Becton Dickinson and the start of work in the status of an independent public company specializing in the treatment of diabetes, as well as about entering the NASDAQ exchange under the EMBC ticker.

In Russia, pen needles and insulin syringes will still be available under the BD Micro-Fine Plus brand.

As a separate public company, embecta aims to develop its product portfolio and achieve a more efficient allocation of resources and capital to satisfy patients with diabetes. In addition, the company will be able to serve the growing insulin delivery market, which ranges from 6 to 8 billion dollars a year, representatives of embecta noted.

"As a manufacturer of diabetes injection devices, embecta has great potential to increase shareholder value and accelerate growth by investing in both organic and inorganic innovations that will help give the necessary knowledge and tools to people living with diabetes," said Devdatt "Dev" Kurdikar, CEO (CEO) embecta.

The main activity of embecta is the constant demand for insulin. According to the International Diabetes Federation, as of April 2022, one in 10 people worldwide suffer from diabetes, and rates of diagnosis, treatment and care are growing, especially in emerging markets. In the absence of the necessary therapy, diabetic patients face many medical complications and comorbidities. Therefore, embecta is an integral part of the system of effective assistance to people with this disease, the company emphasized.

2021

Rename to embecta

In December 2021, it was announced that the BD Diabetes Care business, which Becton Dickinson plans to separate into a separate public company in 2022, will be called embecta. Part of the name of the new company "bet" is inherited from Becton, Dickinson and Company. The "em-" prefix symbolizes empathy (em-pathy) for people living with diabetes, and also means the empowerment of the new company and its team in search of new ways of growth (em-powerment).

Separate Company

On May 25, 2021, the company Becton Dickinson (BD) Zdrav.Expert announced the allocation of one of its divisions, diabetes mellitus BD Diabetes Care, to a separate public company. As a result of the reorganization, companies will be able to optimize their product portfolio, which will further focus on the needs of patients and customers. The portfolio of the created company will include BD products for insulin injections.

BD plans to complete the reorganization in the first half of 2022, after receiving all necessary documents and regulatory approvals. The company will be headed by Dev Kurdikar, current international president of BD's Diabetes Care division.

Business autonomy is expected to enable:

• Increase attention to strategic, operational and financial factors to accelerate revenue growth;
• Optimize product portfolios to better meet customer and patient needs;
• It is more efficient to allocate resources and capital to achieve the strategic goals of each company.

We are confident that this event will reveal additional opportunities for patients with diabetes mellitus, the number of which is steadily growing worldwide. BD Diabetes Care has a strong reputation for innovative technology and advanced manufacturing, sound and stable strategy, and cost-effective financial performance. Every year we produce about 8 billion products for injections and needs of 30 million patients with diabetes mellitus - more than any other company in the world, said Sergey Rubin, Head of Bekton Dickinson B.V. Company Representative Office in Russia and CIS.

Pending completion of the reorganization, we are operating as usual and will do our utmost to avoid any inconvenience to our patients, customers and partners, noted Alexander Barsamyan, Head of Diabetes in Russia and CIS, Bekton Dickinson B.V.

1924: First specialized insulin syringe

The Diabetes Treatment division began operations almost 100 years ago - when BD introduced the first specialized insulin syringe to the market in 1924.